AURX · XBRL financial data

Nuo Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AURX's year ends in late December)

In thousands of dollars	FY 2018Dec 31, 2018	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of revenue	163	—	—	—	—	—
Cost of goods and services sold	163	0	19	126	303	1,096
Gross profit	1,208	0	93	482	1,062	2,218
Research and development	576	0	—	—	—	—
Selling, general and administrative	—	91	3,414	3,651	3,520	4,735
General and administrative	2,021	91	—	—	—	—
Total operating expenses	2,712	91	3,414	3,651	3,520	4,735
Operating income (loss)	(1,505)	(91)	(3,321)	(3,168)	(2,458)	(2,517)
Interest expense	39	0	—	—	—	—
Other income (expense)	2	0	5	0	0	5
Income tax expense (benefit)	—	0	0	0	0	0
Net income (loss)	(1,542)	(91)	(3,172)	(3,171)	(2,324)	(2,512)
Earnings per share, basic USD per share	(0.07)	(0.03)	(0.08)	(0.08)	(0.05)	(0.05)
Earnings per share, diluted USD per share	(0.07)	(0.03)	—	—	—	—
Weighted average shares, basic thousands of shares	23,279	30,296	40,001	42,078	45,424	47,313
Weighted average shares, diluted thousands of shares	23,279	30,296	—	—	—	—

Fiscal years (AURX's year ends in late December)

In thousands of dollars	FY 2018Dec 31, 2018	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	637	1,415	2,051	929	284	549
Accounts receivable	—	0	92	251	248	562
Inventory	25	0	240	210	150	214
Prepaid and other current assets	182	51	196	174	159	56
Total current assets	867	1,466	2,635	1,563	842	1,380
Property and equipment, net	105	0	53	45	177	366
Right-of-use asset	—	0	359	269	171	99
Total assets	975	1,466	3,047	1,878	1,190	1,846
Accounts payable	437	527	398	395	219	436
Accrued liabilities	285	147	123	189	292	494
Total current liabilities	1,057	673	600	675	578	1,306
Lease liability, non-current	—	0	256	164	97	21
Total liabilities	1,057	673	856	839	676	2,802
Accumulated deficit	(22,217)	(23,593)	(26,765)	(29,936)	(32,260)	(34,772)
Total stockholders' equity	(82)	793	2,191	1,039	514	(957)
Total liabilities and equity	975	1,466	3,047	1,878	1,190	1,846
Common shares outstanding (cover page) thousands of shares	23,722	37,124	41,799	44,242	46,816	48,289

Fiscal years (AURX's year ends in late December)

In thousands of dollars	FY 2018Dec 31, 2018	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(1,542)	(91)	(3,172)	(3,171)	(2,324)	(2,512)
Stock-based compensation	7	14	9	22	57	86
Depreciation and amortization	102	0	—	—	—	—
Net cash from operating activities	(874)	(120)	(3,706)	(3,168)	(2,232)	(865)
Purchases of property and equipment	—	0	60	7	155	275
Net cash from investing activities	2	0	(60)	(7)	(155)	(275)
Proceeds from issuing common stock	500	0	—	1,998	1,500	791
Net cash from financing activities	816	1,373	4,458	1,998	1,742	1,405
Net change in cash	(57)	1,253	692	(1,178)	(645)	265

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
Milestone Scientific	2,067	not reported	(585)*	88.7M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
Vicarious Surgical	1,407	not reported	(6,325)	not reported	0.6 quarters	Q1 FY26 10-QMar 31, 2026
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Xtant Medical Holdings	9,870	23,031	(7,308)*	140.3M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Modular Medical	3,920	not reported	(5,972)	8.2M	0.7 quarters	Q1 FY27 10-QJun 30, 2026
Vivani Medical	19,894	not reported	(6,035)*	90.2M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
HeartBeam	8,722	not reported	(3,342)*	56.3M	2.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.